Summary Dose intensity may be an important deterrminant of the outcome in cancer chemotherapy. but is often limited by cumulative haematological toxicity. The availability of haematopoietic growth factors such as granulocyte colony-stimulating factor (G-CSF) and of peripheral blood progenitor cell (PBPC) transplantation has allowed the development of a new treatment strategy in which several courses of high-dose combination chemotherapy are administered for the treatment of solid tumours. PBPCs were mobilised before chemotherapy using 12 or 30 Ljg kg day' G-CSF (Filgrastim) for 10 days, and were collected by 2-5 leucaphereses. The yields of mononuclear cells, colony-forming units and CD34-positive cells were similar at the two dose levels of Filgrastim, and the numbers of PBPCs were sufficient for rescue following multiple cycles of chemotherapy. High-dose chemotherapy (cyclophosphamide 2.5 g m-2 for 2 days, etoposide 300 mg m-for 3 days and cisplatin 50 mg m2 for 3 days) was administered sequentially for a median of three cycles (range 1-4) to ten patients. Following the 30 evaluable cycles, the median duration of leucopenia S 0.5 x 1091-1 and < 1.0 x 10 I`l was 7 and 8 days respectively. The median time of thrombopenia S 20 x 109 1' was 6 days. There was no cumulative haematological toxicity. The duration of leucopenia, but not of thrombopenia, was inversely related to the number of reinfused CFU-GM (granulocyte-macrophage colony-forming units). In the majority of patients, neurotoxicity and ototoxicity became dose limiting after three cycles of therapy. However, the average dose intensity delivered was about three times higher than in a standard regimen. The complete response rate in patients with small-cell lung cancers was 66% (95% CI 30-92%) and the median progression-free survival and overall survival were 13 months and 17 months respectively. These results are encouraging and should be compared, in a randomised fashion, with standard dose chemotherapy.
Small-cell lung cancer (SCLC) has been shown to be sensitive to a variety of single agents and combination chemotherapy, but the early emergence of resistant tumour cells remains the main cause of treatment failure. The effect of dose on tumour response is well established (Antman and Souhami, 1993) , even if the impact on survival is unclear. There are suggestions that the initial administration of high doses of chemotherapy improves disease-free and overall survival in patients with limited disease (Arriagada et al., 1993) . It emphasises the importance of initial intensity in overcoming the development of resistant tumour cells. In experimental models, repeated cycles of chemotherapy have been shown, to be more cytotoxic than a single one (Teicher et al., 1989) . Based on these data, we attempted to develop an intensive regimen of combination chemotherapy that could be administered over multiple sequential cycles in unpretreated patients and to obtain a 3-to 4-fold intensification of chemotherapy compared with a standard regimen.
The chemotherapy regimen consisted of a combination of cyclophosphamide, etoposide and cisplatin. These agents were selected because of their dose-response in SCLC and their synergism in animal models (Johnson et al., 1987) . For each agent, a dose intensity which is known to produce only minimal non-haematological toxicity was chosen. Haematological toxicity was expected, but in order to reduce its duration and to avoid a cumulative exhaustion of haematopoiesis, peripheral blood progenitor cell (PBPC) transplantation and granulocyte colony-stimulating factor (Filgrastim) were used as haematological support. We planto give four cycles of intensive combination chemotherapy, and according to dose intensity calculations (Hryniuk, 1988) the average relative dose intensity of our regimen was projected to be four times higher than a standard regimen administered for six cycles (Cortes Funes et al., 1982) . The feasibility of such an approach was the aim of our study.
Patients and methods
Between June 1992 and January 1994, ten patients enrolled on the study. To be eligible, patients had to have normal cardiac, hepatic and renal functions, a performance status <2 according to ECOG (Oken et al., 1982) , to have given informed consent and to be <65 years old. Patients who had received chemotherapy or colony-stimulating factors in the preceding 12 months were excluded. The study was designed to include patients with a biopsy-proven SCLC, but one 30-year-old woman with metastatic breast cancer to the lung was also entered to test the feasibility of the programme. Acute toxicity was recorded according to the World Health Organization (1979) criteria. Limited disease was defined as that confined to one hemithorax, mediastinum and supraclavicular nodes, provided all volumes could be included in the same radiaotherapy field as the primary tumour. The presence of ipsilateral pleural effusion was classified as limited disease. All the other conditions were considered as extensive disease (Stahel et al., 1989 (Pike and Robinson, 1970 (Siegel, 1956 ). Analysis of diseasefree survival or overall survival was done using the Kaplan-Meier method (Kaplan and Meier, 1958) . Dose inteIsity (DI) was calculated according to Hryniuk (1988) and Longo et at., (1991 The durations of leucopenia and thrombopenia were calculated from the day of PBPC reinfusion to recovery and as the number of days with low leucocyte or thrombocyte counts. The overall median time to leucocyte counts > 0.5 and l.0x 109'-' was 9 (range 8-14) and 10 days (range 8-15) respectively. The median duration with a leucocyte count <0.5 and < 1.0 x 109I' -was 7 days (range 5-12) and 8 days (range 6-13). As seen in Figure ,I0 x I04kg-', the median time to a leucocyte count of 1.0 x 101-l was 11 days (range 9-15). It was 9 days (range 8-10) with a CFU-GM count of > I0 x 0I kg-'. This difference was highly significnt (P = 0.001). The number of CFU-GM kg-' transfused had no influence on platelet recovery > 20 x 10' 1-'. After the administation of >10 or <10X0 0 x kg-' CFU-GM, median duration of platelet recovery was 10.5 days (range 9-14) and 12 days (range 9-15) respctively (P>0.1).
Proven Wall et al., 1994) . The dose of Filgrastim did not affect the rate of leucocyte or platelet recovery or modify the incidence of infections, the number of days on antibiotics or the duration of hospitalisation. Low-dose Filgrastim might be as effective. Indeed, in a randomised trial, even though the dose of 20 ligkg-' day-' G-CSF was marginally more effective than 5 or 10 ;Lg kg-' day'-following bone marrow transplantation, the dose of 5 g kg-' day-' was recommended for further trials (Linch et al., 1993) .
The anti-tumour activity of our regimen was substantial, with a 66% complete response rate (95% CI 30-92%). which is similar to other intensive treatment strategies (Souhami et al., 1985; Johnson et al.. 1987) . It resulted in a median progression-free survival of 13 months and an overall survival of 17 months, possibly because of the selection of patients with good physical condition. However, these results are encouraging and in the range of the best reported results for the treatment of patients with limited disease (Elias et al., 1993) .
Further improvements in the design of intensive treatment strategies may be possible. Radiotherapy might have a role in controlling bulky or localised disease and should be integrated without compromising the delivery of chemotherapy. Other combinations of chemotherapeutic agents might be more suitable for sequential intensive treatment. The intensification of our regimen was mainly due to the ability to increase the dose intensity of cyclophosphamide eight times and that of etoposide 1.8 times. Cisplatin dosage could not be increased significantly and was the cause of limiting toxicity. A combination of alkylating agents or the use of anthracyclines may be more appropriate (Murray, 1987) . We are currently testing the sequential administration of multiple cycles of high-dose ICE (ifosfamide-carboplatin-etoposide), which will be evaluated in a randomised fashion against conventional dose therapy.
